VIRX (Viracta Therapeutics) Other Stockholders Equity: $-0.00 Mil (As of Sep. 2024)


What is Viracta Therapeutics Other Stockholders Equity?

Viracta Therapeutics VIRX Other Stockholders Equity is $-0.00 Mil as of Sep. 2024.

Viracta Therapeutics's Other Stockholders Equity for the quarter that ended in Sep. 2024 was $-0.00 Mil.

Viracta Therapeutics's quarterly Other Stockholders Equity increased from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($0.00 Mil) but then declined from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($-0.00 Mil).

Viracta Therapeutics's annual Other Stockholders Equity declined from Dec. 2021 ($-0.00 Mil) to Dec. 2022 ($-0.00 Mil) but then increased from Dec. 2022 ($-0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Viracta Therapeutics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Viracta Therapeutics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viracta Therapeutics Other Stockholders Equity Chart

Viracta Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
-0.00 -0.00 -0.00 -0.00

Viracta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 -0.00 0.00 -0.00

Viracta Therapeutics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.00 Mil mean?
Viracta Therapeutics (VIRX) has a Other Stockholders Equity of $-0.00 Mil as of Sep. 2024. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Viracta Therapeutics and its competitors.
Is Viracta Therapeutics' Other Stockholders Equity too high?
Viracta Therapeutics' current Other Stockholders Equity is $-0.00 Mil.
How does Viracta Therapeutics' Other Stockholders Equity compare to TSOI and CYTOF?
Viracta Therapeutics' Other Stockholders Equity of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Viracta Therapeutics and its competitors. Viracta Therapeutics's current Other Stockholders Equity is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viracta Therapeutics stock overvalued right now?
Viracta Therapeutics (VIRX) has a current Other Stockholders Equity of $-0.00 Mil. The current Other Stockholders Equity is $-0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Viracta Therapeutics (VIRX), the current Other Stockholders Equity is $-0.00 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viracta Therapeutics Business Description

Address 2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.